Is it time to REWIND the cardiorenal clock in diabetes?

Affiliations

¹ Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto M5B 1W8, ON, Canada; Department of Surgery, Department of Pharmacology, and Department of Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address: vermasu@smh.ca.
² Department of Anesthesia, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto M5B 1W8, ON, Canada; Department of Anesthesia and Department of Physiology, University of Toronto, Toronto, ON, Canada.
³ Department of Renal Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia; Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales Sydney, NSW, Australia.

Comment

Subodh Verma et al. Lancet. 2019.

. 2019 Jul 13;394(10193):95-97.

doi: 10.1016/S0140-6736(19)31267-X. Epub 2019 Jun 9.

¹ Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto M5B 1W8, ON, Canada; Department of Surgery, Department of Pharmacology, and Department of Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address: vermasu@smh.ca.
² Department of Anesthesia, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto M5B 1W8, ON, Canada; Department of Anesthesia and Department of Physiology, University of Toronto, Toronto, ON, Canada.
³ Department of Renal Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia; Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales Sydney, NSW, Australia.

No abstract available

Comment on

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.